Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 1977New England Journal of Medicine

Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload

View Full Paper
Ask AI
Bookmark
Share

Authors

RPRichard D. PropperHCI International Medical CentreBCBarry CooperBaylor University Medical CenterRRR RufoUniversity of Pennsylvania

Discussion

Loading...

Member takes

Overview

Clinical study demonstrates continuous subcutaneous deferoxamine enhances urinary iron excretion in iron overload, indicating an effective alternative to intravenous therapy.

Key Points

  • To evaluate whether continuous 24-hour intravenous and subcutaneous infusions of deferoxamine can achieve net negative iron balance in patients with siderosis.
  • Evaluated 24 patients with siderosis who had an average baseline iron excretion of 420 to 630 mg (mean, 480 mg) per month on daily 0.75 g intramuscular injections.
  • Administered deferoxamine B as a constant 24-hour infusion, comparing urinary iron excretion between intravenous and subcutaneous administration routes.
  • Intravenous deferoxamine infusion increased monthly urinary iron excretion to a range of 570 to 3690 mg (mean, 1595 mg per month).
  • Continuous subcutaneous delivery was 90% as effective as intravenous administration on a dose-for-dose basis, sustaining net cumulative iron excretion exceeding 1 g per month in all patients.

Cite This Study

Propper et al. (1977) studied this question.

synapsesocial.com/papers/6a90d27bda08d7e10a82f727https://doi.org/10.1056/nejm197708252970804
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Hemochromatosis and Hemosiderosis1963 · 121 citations